Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Rabeximod
Therapeutic Area: Infections and Infectious Diseases Product Name: Rob 803
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
An approval of the application will strengthen the company’s intellectual property portfolio and generate a longer market exclusivity for Rabeximod.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VP01
Therapeutic Area: Infections and Infectious Diseases Product Name: C21
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2020
Details:
The primary objective with the study, named ATTRACT (Angiotensin II Type Two Receptor Agonist Covid-19 Trial), is to investigate efficacy of VP01 (C21) on COVID-19 infection not requiring mechanical ventilation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VP01
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2020
Details:
Vicore Pharma got approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to start a Phase II clinical trial assessing a potential COVID-19 therapy in record time.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
